GlassScriptPhysician profile
William B Calhoun
NPI 1932219177
$3,414.04
in general payments reported to CMS, 2019-2025
32 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $213 · 2021: $455 · 2022: $737 · 2023: $501 · 2024: $497 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.12 | 2019-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $342.84 | 2021-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $289.96 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $282.74 | 2019-2025 | |
| Pfizer INC. | $247.62 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $245.66 | 2019-2025 | Wainua |
| Atricure, INC. | $201.25 | 2020-2021 | |
| Boston Scientific Corporation | $181.50 | 2022-2025 | General - Vascular Intervention, Lux-Dx Insertable Cardiac Monitor, Ranger |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $157.08 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $136.81 | 2019-2022 | |
| Amgen INC. | $108.84 | 2020-2024 | Repatha |
| Abbott Laboratories | $106.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $95.49 | 2019-2023 | |
| Lilly USA, LLC | $87.10 | 2019 | |
| Irhythm Technologies, INC. | $64.45 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $61.46 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $55.53 | 2019 | |
| Daiichi Sankyo INC. | $46.93 | 2024-2025 | Injectafer |
| Daxor Corporation | $41.15 | 2024 | Bva-100 |
| Novo Nordisk INC | $39.63 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $38.22 | 2022 | |
| Bracco Diagnostics INC. | $32.75 | 2023 | |
| Abiomed | $32.70 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $27.43 | 2019 | |
| Scpharmaceuticals INC. | $23.58 | 2025 | |
| Akcea Therapeutics, INC. | $22.89 | 2019-2020 | |
| Nuwellis, INC. | $19.92 | 2024 | Aquadex Smartflow Console |
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2025 | |
| Astellas Pharma US INC | $15.26 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.94 | 2024 | |
| Bridgebio Pharma, INC. | $13.91 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.